{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dapagliflozin
to a specific field?
Status:
Possibly Marketed Outside US
Source:
ANDA079009
(2013)
Source URL:
First approved in 2009
Source:
M001
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
NCT03992716: Phase 4 Interventional Terminated Critical Illness
(2019)
Source URL:
First approved in 1971
Source:
NDA016822
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Proline (L-Proline) is one of the twenty amino acids used in living organisms as the building blocks of proteins. Proline is a non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. Proline is used in pharmaceuticals as an excipient and as an active substance in nutritional supplements. Proline is not commonly used in pharmaceuticals as an excipient. It is approved for use in Privigen (IVIg) and Hizentra (SCIg) solution for injection as a stabiliser for IgG. Proline is also contained in low amounts in several vaccines, e.g. Havrix 720 Kinder (Hepatitis A).
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2020)
Source URL:
First approved in 1965
Source:
ANDA074464
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
NCT02495324: Phase 4 Interventional Completed Essential,Hypertension
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
